Urosdeoxycholic acid in primary sclerosing cholangitis: A meta-analysis and systematic review

Arab Journal of Gastroenterology

Volumn 13, Issue 3, 2012, Pages 103-110

  Othman, Mohamed O ^a   Dunkelberg, Jeffery ^b   Roy, Praveen K ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MARSHFIELD CLINIC   (United States)

Author keywords

Cholangiocarcinoma; Meta analysis; Primary sclerosing cholangitis; Urosdeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; CANCER INCIDENCE; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; HUMANS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84868302066     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2012.06.011     Document Type: Review

References (44)

1. Silveira M.G., Lindor K.D. Primary sclerosing cholangitis. Can J Gastroenterol 2008, 22(8):689-698.
2. Saich R., Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory Bowel disease. World J Gastroenterol 2008, 14(3):331-337.
3. Tischendorf J.J.W., Hecker H., Krüger M., et al. Characterization, outcome and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102(1):107-114.
4. Tanaka A., Takamori Y., Toda G., et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int 2008, 28(7):983-989.
5. Ponsioen C.Y., Vrouenraets S.M.E., Prawirodirdjo W., et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002, 51(4):562-566.
6. Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape Gen Med 2008;10(3):Art. No. 61.
7. Ward A., Brogden R.N., Heel R.C. Ursodeoxycholic acid. A review of its pharmacological properties and therapeutic efficacy. Drugs 1984, 27(2):95-131.
8. Heuman D.M., Mills A.S., McCall J., et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts: In vivo studies in the rat. Gastroenterology 1991, 100(1):203-211.
9. Heuman D.M., Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994, 106(5):1333-1341.
10. Fiorotto R., Spirlì C., Fabris L., et al. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007, 133(5):1603-1613.
11. Colombo C., Castellani M.R., Balistreri W.F., et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992, 15(4):677-684.
12. Nishigaki Y., Ohnishi H., Moriwaki H., et al. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 1996, 41(7):1487-1493.
13. Yoshikawa M., Tsujii T., Matsumura K., et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992, 16(2):358-364.
14. Cochrane handbook for systematic reviews of interventions [homepage on the Internet], 2008.
15. Beuers U., Spengler U., Kruis W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16(3):707-714.
16. De Maria N., Colantoni A., Rosenbloom E., et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996, 43(12):1472-1479.
17. Lindor K.D. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336(10):691-695.
18. Lindor K.D., Kowdley K.V., Luketic V.A.C., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50(3):808-814.
19. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121(4):900-907.
20. Olsson R., Boberg K.M., Schaffalitsky De Muckadell O., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129(5):1464-1472.
21. Stiehl A., Walker S., Stiehl L., et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20(1):57-64.
22. Van De Meeberg P.C., Wolfhagen F.H.J., Van Berge Henegouwen G.P., et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol 1996, 25(6):887-894.
23. Van Hoogstraten H.J.F., Vleggaar F.P., Boland G.J., et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol 2000, 95(8):2015-2022.
24. Cullen S.N., Rust C., Fleming K., et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008, 48(5):792-800.
25. Van Hoogstraten H.J.F., Wolfhagen F.H.J., Van De Meeberg P.C., et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29(3):417-423.
26. Färkkilä M., Karvonen A.L., Nurmi H., et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40(6):1379-1386.
27. Sterling R.K., Salvatori J.J., Luketic V.A., et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Alimen Pharmacol Ther 2004, 20(9):943-949.
28. Lo S.K., Herrmann R., Chapman R.W. Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology 1992, 16:A92.
29. Bansi D., Christie J., Fleming K. Ursodeoxycholic acid in primary sclerosing cholangitis: a double blind placebo controlled trial. Hepatology 1992, 16:92A.
30. Garioud A., Seksik P., Chrétien Y., et al. Characteristics and clinical course of primary sclerosing cholangitis in France. A prospective Cohort study. Eur J Gastroenterol Hepatol 2010, 22(7):842-847.
31. Chazouilleres O., Poupon R., Capron J.P., et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990, 11(1):120-123.
32. Podda M., Ghezzi C., Battezzati P.M., et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989, 34(12 Suppl.):59S-65S.
33. O'Brien C.B., Senior J.R., Arora Mirchandani R., et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991, 14(5):838-847.
34. Van Milligen De Wit A.W.M., Kuiper H., Camoglio L., et al. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?. Eur J Gastroenterol Hepatol 1999, 11(2):129-136.
35. Harnois D.M., Angulo P., Jorgensen R.A., et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96(5):1558-1562.
36. Brandsæter B., Isoniemi H., Broomé U., et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40(5):815-822.
37. Pardi D.S., Loftus E.V., Kremers W.K. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124(4):889-893.
38. Tung B.Y., Emond M.J., Haggitt R.C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134(2):89-95.
39. Sjöqvist U., Tribukait B., Öst Å, et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004, 24(5 B):3121-3127.
40. Serfaty L., De Leusse A., Rosmorduc O., et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003, 38(1):203-209.
41. Alberts D.S., Martínez M.E., Hess L.M., et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005, 97(11):846-853.
42. Lindor K.D., Jorgensen R.A., Anderson M.L., et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996, 91(3):511-515.
43. Chen W., Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003, (2):CD003626.
44. Shi J., Li Z., Zeng X., et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009, 39(9):865-873.